Please use this identifier to cite or link to this item:
Title in Portuguese: Tumor suppressor p53 protein expression : prognostic significance in patients with low-risk myelodysplastic syndrome
Author: Duarte, Fernando Barroso
Gonçalves, Romelia Pinheiro
Barbosa, Maritza Cavalcante
Rocha Filho, Francisco Dário
Santos, Talyta Ellen de Jesus dos
Santos, Thayna Nogueirados
Vasconcelos, Paulo Roberto Leitão de
Keywords: Proteína Supressora de Tumor p53
Issue Date: May-2014
Publisher: Revista Brasileira de Hematologia e Hemoterapia
Citation: DUARTE, F. B. Tumor suppressor p53 protein expression : prognostic significance in patients with low-risk myelodysplastic syndrome. Rev. bras. hematol. hemoter., São José do Rio Preto, v. 36, n. 3, p. 196–201, 2014.
Abstract: Background: At the time of diagnosis, more than 50% of patients with myelodysplastic syn- drome have a normal karyotype and are classified as having a favorable prognosis. However, these patients often show very variable clinical outcomes. Furthermore, current diagnostic tools lack the ability to look at genetic factors beyond karyotyping in order to determine the cause of this variability. Objective: To evaluate the impact of p53 protein expression at diagnosis in patients with low-risk myelodysplastic syndrome. Methods: This study enrolled 38 patients diagnosed with low-risk myelodysplastic syndrome. Clinical data were collected by reviewing medical records, and immunohisto- chemical p53 staining was performed on bone marrow biopsies. Results: Of the 38 participants, 13 (34.21%) showed p53 expression in their bone marrow. At diagnosis, this group of patients also presented clinical features characteristic of a poor prognosis more often than patients who did not express p53. Furthermore, patients express- ing p53 had a shorter median survival time compared to those without p53 expression. Conclusion: This study shows that the expression of p53 at diagnosis is a useful indicator of distinct clinical characteristics and laboratory profiles found in low-risk myelodysplastic syndrome patients. These data indicate that the immunohistochemical analysis of p53 may be a prognostic tool for myelodysplastic syndrome and should be used as an auxiliary test to help determine the best therapeutic choice.
ISSN: 1516-8484
Appears in Collections:DFAR - Artigos publicados em revistas científicas

Files in This Item:
File Description SizeFormat 
2014_art_tejsantos.pdf501,2 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.